Radical Cystectomy with Urinary Diversion — Cost, Top Hospitals & Success Rates | MyMedicPlus

Radical cystectomy with urinary diversion is the gold-standard surgical treatment for muscle-invasive bladder cancer (MIBC) and selected cases of high-risk, recurrent non-muscle-invasive bladder cancer. It involves complete removal of the urinary bladder along with adjacent pelvic organs and lymph nodes, followed by surgical reconstruction of a new urinary drainage system — the urinary diversion — to allow the body to excrete urine.

Bladder cancer is the tenth most common cancer globally, with approximately 550,000 new cases diagnosed annually. Muscle-invasive bladder cancer — where tumour has penetrated into the detrusor muscle — accounts for 25% of new bladder cancer diagnoses and carries a significantly poorer prognosis without definitive treatment. Radical cystectomy, particularly when combined with neoadjuvant platinum-based chemotherapy in eligible patients, remains the treatment offering the highest long-term survival rates for localised MIBC.

The surgical approach may be open (laparotomy), laparoscopic, or robot-assisted laparoscopic (RARC). Robot-assisted cystectomy has grown substantially in adoption over the past decade, offering equivalent oncological outcomes with reduced estimated blood loss and shorter hospital stays in experienced centres. The creation of the urinary diversion — whether an ileal conduit, orthotopic neobladder, or continent cutaneous reservoir — adds significant complexity and duration to the procedure.

This is one of the most complex operations in urology, typically lasting 4–8 hours, and is associated with a 30-day major complication rate of 20–30% even in high-volume centres. Optimal outcomes are achieved at centres performing more than 20 cystectomies per year with multidisciplinary support including stoma nurses, oncologists, physiotherapists, and sexual health counsellors.

Radical cystectomy is indicated for the following conditions:

• Muscle-invasive bladder cancer (MIBC, cT2–T4a, N0M0): The primary indication. Tumour invasion into the detrusor muscle layer requires radical treatment; radical cystectomy with neoadjuvant chemotherapy offers the best curative intent outcomes.
• High-grade non-muscle-invasive bladder cancer (NMIBC) failing BCG: High-grade T1 or carcinoma in situ (CIS) bladder cancer that fails to respond to 2 courses of intravesical bacillus Calmette-Guérin (BCG) therapy, or high-risk T1 with CIS or multifocal disease, carries a significant risk of progression and is best treated by early cystectomy.
• Rapidly recurrent high-grade NMIBC: Repeated high-grade recurrence despite adequate intravesical therapy, particularly with BCG-unresponsive status (as defined by AUA/EAU guidelines).
• Bladder cancer with complications: Severe, recurrent haematuria uncontrolled by other means, painful contracted bladder (bladder contracture), or fistula formation.
• Selected cases of squamous cell carcinoma or adenocarcinoma of the bladder.
• Bladder exstrophy or complex reconstruction in rare congenital conditions (salvage cystectomy).

In node-positive (N+) or metastatic (M1) bladder cancer, radical cystectomy may still be considered as part of multimodal therapy with palliative intent (symptom control) or in the context of clinical trials.

Careful patient selection optimises surgical outcomes and minimises risk of major complications:

• Performance status: Patients should have an ECOG performance status of 0–2 and adequate cardiopulmonary reserve to withstand a 4–8 hour major operation under general anaesthesia.
• Renal function: Adequate renal function (GFR >40–50 mL/min) is required for neoadjuvant cisplatin-based chemotherapy and is essential for construction of a urinary diversion using bowel segments, which require sufficient renal clearance to prevent metabolic complications.
• Absence of distant metastases: Staging with CT chest/abdomen/pelvis ± bone scan confirms curative intent. Clinical T stage (cT2–T4a) and N0 disease are standard eligibility criteria for curative cystectomy.
• Urethral integrity: Orthotopic neobladder requires a tumour-free urethra (confirmed by urethral frozen section at surgery); carcinoma in situ or tumour at the bladder neck or urethra precludes neobladder construction and mandates urethrectomy.
• Bowel integrity: Prior pelvic radiation or inflammatory bowel disease affecting ileum may complicate urinary diversion construction; alternative bowel segments (sigmoid, right colon) or simpler diversion strategies may be required.
• Patient willingness and capacity: The patient must understand and accept the permanent life change entailed by bladder removal and urinary diversion, including stoma management (ileal conduit) or clean intermittent self-catheterisation (neobladder/continent pouch).

Elderly patients (>75 years) are not excluded based on age alone; physiological age and comorbidity burden are more important determinants of risk than chronological age.

Radical cystectomy encompasses two inseparable decisions: the surgical approach (how the bladder is removed) and the urinary diversion type (how urine is managed afterwards).

Surgical Approaches

Open Radical Cystectomy: Traditional approach via a midline laparotomy incision. Well-established with the longest outcome data. Preferred for complex anatomies, prior abdominal surgery, or when extended lymph node dissection is planned.

Laparoscopic Radical Cystectomy: Minimally invasive; urinary diversion is typically constructed extracorporeally (outside the body). Longer learning curve; less commonly performed than robotic approach.

Robot-Assisted Radical Cystectomy (RARC): The da Vinci robotic platform allows precise dissection with 3D magnification and wristed instruments. The RAZOR trial (2018) demonstrated non-inferiority to open cystectomy in 2-year recurrence-free survival. Intracorporeal urinary diversion (performed entirely inside the body robotically) is increasingly performed at expert centres, with shorter hospital stays and less blood loss. Requires significant surgeon training and institutional investment.

Urinary Diversion Types

Ileal Conduit (Bricker Conduit) — most common: A 15–20 cm segment of ileum is isolated from the small bowel, the ureters are anastomosed to one end, and the other end is brought to the skin as a stoma (urostomy). Urine drains continuously into an external appliance (bag) worn on the abdominal wall. Simplest, shortest procedure; lowest early complication rate; suitable for most patients. Long-term complications include stomal stenosis (10%), upper tract dilation, urinary tract infections, and urolithiasis.

Orthotopic Neobladder (Studer, Hautmann): A spherical reservoir is fashioned from 50–60 cm of detubularised ileum and anastomosed to the urethra, allowing the patient to void per urethra by abdominal straining (Valsalva). Most closely mimics normal bladder function. Requires an intact urethra with clear margins. Daytime continence: 85–90%; Night-time continence: 70–80%. Approximately 10–15% require intermittent catheterisation. Risk of hyperchloraemic metabolic acidosis from ileal segment absorption.

Continent Cutaneous Reservoir (Indiana Pouch, Kock Pouch): An internal pouch constructed from bowel is catheterised through a continent stoma (typically at the umbilicus) 4–6 times daily, with no external bag required. Preferred by some patients who want reservoir function without urethral voiding. Requires excellent manual dexterity and commitment to regular catheterisation.

• Curative intent: For organ-confined MIBC, radical cystectomy offers the highest prospect of cure — 5-year cancer-specific survival of 70–75% for pT2N0 disease.
• Eliminates primary tumour: Complete removal of the bladder eliminates the risk of local tumour progression, further invasive growth, fistula formation, or severe haemorrhage from the primary tumour.
• Comprehensive pelvic lymphadenectomy: Extended pelvic lymph node dissection removes microscopic nodal metastases and provides accurate staging to guide adjuvant treatment decisions.
• Multiple diversion options: Modern urinary diversion techniques allow individualised reconstruction that can preserve quality of life, with neobladder construction offering near-natural voiding function in eligible patients.
• Improved survival with neoadjuvant chemotherapy: Combining chemotherapy with surgery improves 5-year overall survival by 5–8% and achieves pathological complete response in 20–35% of patients.
• Symptom control: Eliminates haematuria, painful bladder contracture, recurrent infections, and obstructive uropathy from invasive tumour.
• Established, reproducible procedure: Decades of refinement have produced standardised techniques with predictable outcomes at high-volume centres.

Radical cystectomy is one of the most complex and morbid urological operations. 30-day complication rates at experienced centres range from 20–30% for major complications and up to 60% for any complication:

Intraoperative

• Blood loss requiring transfusion (10–30%)
• Rectal or vascular injury (1–2%)
• Ureteric injury

Early Post-operative (within 90 days)

• Ileus and bowel obstruction: Most common complication; occurs in 5–20% due to bowel handling and adhesion formation.
• Urinary leakage: Anastomotic leak at ureterointestinal or urethral anastomosis (5–10%).
• Wound infection and dehiscence: Particularly in obese patients or those with prior abdominal surgery.
• Deep vein thrombosis / pulmonary embolism: Major pelvic surgery carries significant VTE risk; prophylaxis with LMWH and early mobilisation is mandatory.
• Infection: Urinary tract infection, sepsis, pneumonia.
• Mortality: 30-day mortality is approximately 1–3% at high-volume centres; higher in comorbid or elderly populations.

Long-term

• Stomal complications (ileal conduit): Stenosis, parastomal hernia, retraction (10–20% over 10 years).
• Upper urinary tract complications: Ureteroileal stricture, hydronephrosis, renal deterioration.
• Metabolic abnormalities: Hyperchloraemic metabolic acidosis (especially neobladder), vitamin B12 deficiency from ileal resection (requiring supplementation).
• Sexual dysfunction: Erectile dysfunction in men (60–80% without nerve sparing), vaginal dryness and dyspareunia in women.
• Urinary incontinence / retention (neobladder): Night-time incontinence 20–30%; retention requiring catheterisation 10–15%.
• Urinary tract infections and nephrolithiasis.

Recovery from radical cystectomy is a prolonged process requiring multidisciplinary support:

Hospital Stay (7–14 days)

Enhanced Recovery After Surgery (ERAS) protocols — including early mobilisation, multimodal analgesia, early oral nutrition, and prophylactic ileus management — have reduced hospital stays from 2–3 weeks to 7–10 days at most centres. A nasogastric tube is typically removed within 48 hours. The urinary catheter (neobladder) or urostomy is evaluated for output and leakage before discharge. Nutritional support and stoma nursing education are provided before leaving hospital.

First Month

Gradual increase in activity; no driving for 4–6 weeks; no heavy lifting for 8 weeks. Stoma management education with a specialist stoma nurse is essential for ileal conduit patients. Neobladder patients undergo voiding training: learning to void by abdominal straining every 3 hours and performing pelvic floor exercises to improve continence.

Oncological Follow-Up

Post-operative staging determines whether adjuvant chemotherapy is needed (pT3/T4 or pN+ disease). CT chest/abdomen/pelvis is performed at 3, 6, 12, 18, and 24 months post-surgery, then annually for 5 years to detect disease recurrence. Upper urinary tract surveillance (renal ultrasound or CT urogram) is performed annually to detect ureteroileal stricture or upper tract tumours.

Functional Rehabilitation

Sexual rehabilitation, pelvic floor physiotherapy, and, where appropriate, hormone replacement therapy (in premenopausal women after bilateral oophorectomy) are initiated early. Vitamin B12 injections every 3 months are required lifelong due to ileal segment resection affecting B12 absorption.

Radical cystectomy is one of the most expensive urological procedures. Major cost drivers include:

• Surgical approach: Robot-assisted cystectomy carries higher equipment and consumable costs (USD 1,500–3,000 additional per case) but may reduce hospital stay costs through faster recovery. Open surgery has lower operative costs but often longer inpatient stays.
• Urinary diversion type: Neobladder or continent pouch construction significantly extends operative time (an additional 1–3 hours) compared to ileal conduit, increasing theatre and anaesthesia costs. Ileal conduit is the least costly diversion to construct.
• Country and centre: In the US, total costs range from USD 25,000–60,000 (open/laparoscopic) to USD 35,000–75,000 (robotic), largely determined by hospital facility fees. In the UK (NHS), the procedure is provided free at point of care; private rates are GBP 15,000–30,000. At JCI-accredited centres in India, comprehensive packages (including pre-operative staging, surgery, and 10-day hospitalisation) are available for USD 5,000–10,000; in Thailand and Turkey, USD 6,000–14,000.
• Neoadjuvant chemotherapy: 3–4 cycles of gemcitabine plus cisplatin add USD 8,000–15,000 in the US; substantially less in India or Thailand.
• Stoma supplies: Ileal conduit stoma appliances cost approximately USD 200–400/month over the patient's lifetime — a significant long-term ongoing cost to factor into decision-making.
• Rehabilitation and follow-up: CT scans, urology visits, stoma nursing, sexual health consultations, and B12 injections contribute substantially to 5-year cumulative costs.

In carefully selected patients, bladder-preserving strategies may be considered, though none have demonstrated equivalent survival to radical cystectomy in head-to-head trials for MIBC:

• Trimodality therapy (bladder preservation for MIBC): Maximal transurethral resection of bladder tumour (TURBT) followed by concurrent chemotherapy (usually cisplatin) and radiotherapy. Achieves complete response in 50–70% and bladder preservation in long-term responders. 5-year survival rates approach 50–60% in highly selected patients at expert centres (BCON, RTOG trials). Reserved for patients unfit for cystectomy or strongly preferring bladder preservation; requires close surveillance for recurrence.
• BCG immunotherapy (for NMIBC): For high-grade non-muscle-invasive cancer, BCG induction followed by maintenance reduces recurrence and progression risk but is not curative for muscle-invasive disease.
• Pembrolizumab (Keytruda) for BCG-unresponsive NMIBC: FDA-approved (2020) for BCG-unresponsive, high-risk NMIBC patients who refuse or are ineligible for cystectomy. Complete response in 41%; durable responses in some patients.
• Chemotherapy alone (palliative): For metastatic or surgically unresectable bladder cancer, cisplatin-based chemotherapy (gemcitabine + cisplatin) remains first-line systemic therapy. Immune checkpoint inhibitors (atezolizumab, pembrolizumab) are second-line options and may be used in cisplatin-ineligible patients first-line.
• Best supportive care: For patients with significant comorbidity, poor performance status, or metastatic disease where aggressive treatment is not appropriate, symptom-directed palliative care — including haematuria management, pain control, and urinary diversion for obstructive uropathy — is the appropriate focus.